These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35442011)

  • 21. Ustekinumab Does Not Increase Risk of Adverse Events: A Meta-Analysis of Randomized Controlled Trials.
    Rolston VS; Kimmel J; Popov V; Bosworth BP; Hudesman D; Malter LB; Hong S; Chang S
    Dig Dis Sci; 2021 May; 66(5):1631-1638. PubMed ID: 32445049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice.
    Ylisaukko-Oja T; Puttonen M; Jokelainen J; Koivusalo M; Tamminen K; Torvinen S; Voutilainen M
    Scand J Gastroenterol; 2022 Apr; 57(4):415-423. PubMed ID: 34927504
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic comparison of anrukinzumab, an anti- IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients.
    Hua F; Ribbing J; Reinisch W; Cataldi F; Martin S
    Br J Clin Pharmacol; 2015 Jul; 80(1):101-9. PubMed ID: 25614144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review.
    Thibodaux RJ; Triche MW; Espinoza LR
    Expert Opin Biol Ther; 2018 Jul; 18(7):821-827. PubMed ID: 29949399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Honap S; Meade S; Ibraheim H; Irving PM; Jones MP; Samaan MA
    Dig Dis Sci; 2022 Mar; 67(3):1018-1035. PubMed ID: 33723700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.
    Jauslin P; Kulkarni P; Li H; Vatakuti S; Hussain A; Wenning L; Kerbusch T
    Clin Pharmacokinet; 2019 Aug; 58(8):1059-1068. PubMed ID: 30915660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases.
    Yang H; Li B; Guo Q; Tang J; Peng B; Ding N; Li M; Yang Q; Huang Z; Diao N; Zhu X; Deng J; Guo H; Hu P; Chao K; Gao X
    Aliment Pharmacol Ther; 2022 Apr; 55(7):764-777. PubMed ID: 35141914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease.
    Wang Z; Verstockt B; Sabino J; Vermeire S; Ferrante M; Declerck P; Dreesen E
    Br J Clin Pharmacol; 2022 Jan; 88(1):323-335. PubMed ID: 34197653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies.
    Dulai PS; Osterman MT; Lasch K; Cao C; Riaz F; Sandborn WJ
    Dig Dis Sci; 2019 Sep; 64(9):2478-2488. PubMed ID: 30923985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ustekinumab for the treatment of Crohn's disease.
    Hansen T; Targownik LE
    Expert Rev Gastroenterol Hepatol; 2016 Sep; 10(9):989-94. PubMed ID: 27450626
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab Inhibits T Follicular Helper Cell Differentiation in Patients With Crohn's Disease.
    Globig AM; Sommer NP; Wild K; Schardey J; Zoldan K; Thomann AK; Schulte LA; Schreiner R; Reindl W; Klaus J; Schempp CM; Hofmann M; Thimme R; Boettler T; Hasselblatt P
    Cell Mol Gastroenterol Hepatol; 2021; 11(1):1-12. PubMed ID: 32679193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of Crohn's disease, aseptic liver abscess and psoriasis with ustekinumab.
    Dai C; Huang YH
    Rev Esp Enferm Dig; 2023 Mar; 115(3):155-156. PubMed ID: 36093978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study.
    Pugliese D; Daperno M; Fiorino G; Savarino E; Mosso E; Biancone L; Testa A; Sarpi L; Cappello M; Bodini G; Caprioli F; Festa S; Laino G; Maconi G; Mazzuoli S; Mocci G; Sartini A; D'Amore A; Alivernini S; Gremese E; Armuzzi A
    Dig Liver Dis; 2019 Jul; 51(7):972-977. PubMed ID: 30992173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease.
    Deepak P; Sandborn WJ
    Gastroenterol Clin North Am; 2017 Sep; 46(3):603-626. PubMed ID: 28838418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
    Barré A; Colombel JF; Ungaro R
    Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.
    Deepak P; Loftus EV
    Drug Des Devel Ther; 2016; 10():3685-3698. PubMed ID: 27956825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and C-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease.
    Li C; Shoji S; Beebe J
    Br J Clin Pharmacol; 2018 Sep; 84(9):2059-2074. PubMed ID: 29776017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SB5: An Adalimumab Biosimilar.
    Frampton JE
    BioDrugs; 2018 Oct; 32(5):507-510. PubMed ID: 30251234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.